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Objective. This is a retrospective interventional case series describing the results of 5 eyes from 5 patients with symptomatic
peripapillary choroidal neovascularization (CNVM) receiving initial bevacizumab treatment followed by thermal laser and
bevacizumab combination therapy. Methods. Patients received intravitreal bevacizumab injections until the lesions were well-
defined. Thermal laser ablation was then administered and followed by an additional bevacizumab injection after one week.
Visual outcomes, OCT changes, and rates of recurrence were recorded and analyzed. Results. Median visual outcomes improved
from 20/50 to 20/30 (p = 0 0232). Median central macular thickness decreased from 347 μm to 152 μm (p = 0 0253). The mean
visual improvement was 3 lines. An average of 3.8 bevacizumab injections per patient were given overall. Patients were followed
for an average of 24 months, during which all eyes were absent for recurrence. Conclusion. Symptomatic peripapillary CNVM
may be successfully managed with bevacizumab followed by a combination of thermal laser and bevacizumab without the need
for frequent retreatment. The area requiring treatment may be better defined using bevacizumab, limiting the ablation of the
healthy retina and improving treatment margins. With this treatment regimen, the patients experience improved visual
outcomes and have a low rate of recurrence.
1. Introduction
Peripapillary or juxtapapillary choroidal neovascular mem-
branes (CNVM) occur in patients due to a variety of
conditions. These CNVM are most often associated with
age-related macular degeneration (45%) or from idiopathic
causes (39%) [1]. Peripapillary CNVM are also known to
occur with other diseases including ocular histoplasmosis
(OHS), angioid streaks, pars planitis, optic disc drusen, choroidal
osteoma, and pattern dystrophies [1]. Peripapillary CNVM are
predominately occult membranes and are often associated with
retinal hemorrhage [2–4]. Some patients are asymptomatic and
may be observed, while other patients present with decreased
vision and metamorphopsia. Symptomatic patients often
require treatment. Traditionally, these CNVMwere ablated with
thermal laser if 1.5 clock hours of retina temporal to the optic
nerve was spared [1, 5–8]. Other treatment modalities have
been utilized including surgical removal of large membranes
associated with OHS [9] and photodynamic therapy [10, 11].
Anti-VEGF agents including intravitreal bevacizumab
(Avastin) and ranibizumab are used to treat subfoveal
CNVM associated with age-related macular degeneration
[12, 13]. These agents are also being utilized to treat various
other conditions associated with choroidal neovasculariza-
tion, including peripapillary CNVM [14, 15]. There is also a
rationale for combining various therapies for CNVM associ-
ated with subfoveal lesions [16] or peripapillary lesions [17].
Thus, in this case series, we examined the outcomes in peri-
papillary CNVM treated first with bevacizumab, followed
by thermal laser and bevacizumab in combination. Visual
outcomes were examined as well as the frequency of injec-
tions and stability of the CNVM after treatment.
2. Methods
This was a retrospective, noncomparative, interventional
case series involving 5 eyes from 5 patients with peripapillary
CNVM identified in clinical practice. Patients who had less
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than six months of follow-up, were asymptomatic, or under-
went previous treatment were excluded from the study. All
patients exhibited decreased vision and metamorphopsia.
Patients had hemorrhage around the CNVM, exudates, and
fluid involving the subfoveal region. Patients were initially
evaluated with a complete ophthalmic examination and fluo-
rescein angiogram (FA). Optical coherence tomography
(OCT) was performed at each follow-up visit.
Following complete evaluation, treatment was initiated
with 1.25mg/0.05ml intravitreal bevacizumab (Avastin,
Genentech, San Francisco) under sterile conditions via pars
plana injection. Patients returned for further evaluation at
four- to six-week intervals. Complete ophthalmic and repeat
OCT examinations were performed at each follow-up visit.
Bevacizumab injections were repeated until the blood had
resolved, the central macular thickness (CMT) was normal-
ized, and the CNVM appeared stabilized clinically. A repeat
FA was obtained to reexamine the lesion once the CNVM
was smaller and well-defined.
Thermal laser (532 nanometer diode laser) was then
applied to the CNVM, and 200 microns beyond the temporal
side of the lesion until retinal whitening occurred. The optic
nerve was not involved in the treatment. Treatment was
administered according to the Macular Photocoagulation
Study (MPS) guidelines [8]. Within one week of laser treat-
ment, an additional bevacizumab injectionwas given. Patients
were thenevaluated for treatment success andsafetybyOCTat
1month and carefullymonitored for any signs of recurrence at
increasing intervals of 6 weeks, 8 weeks, 10 weeks, and then
every 3 months, for a minimum of 15 months.
Pre- and postoperative values for visual acuity and CMT
were compared using the Wilcoxon rank-sum test. A p value
less than 0.05 was considered statistically significant.
3. Results
This study consisted of 3 females and 2 males with an average
age of 74.8 years (range 56–84 years). All patients presented
with occult membranes. Four patients were phakic, and 1
patient was pseudophakic. Evidence of AMD in both eyes
with drusen and retinal pigment epithelial mottling were also
observed in 4 patients. The average initial lesion size includ-
ing hemorrhage and exudates covered approximately 2 disk
areas (range 1–3 disc areas; see Figure 1). The mean number
of clock hours that the CNVM surrounded the optic nerve
was 3.8 (range 3–6). All lesions spared more than 1.5 clock
hours of temporal retina.
The average follow-up period from the first diagnosis of
juxtapapillary CNVM was 31 months (range 25–34 months).
Each patient received an average of 2.8 bevacizumab injec-
tions (range 2–4 injections) prior to thermal laser treatment.
An additional bevacizumab injection was given within one
week. CNVM recurrence was absent for all patients over an
average follow-up period of 24 months (range 21–28 months;
see Table 1) upon completion of thermal laser and final
bevacizumab treatments.
The median preoperative vision was 20/50 (range 20/40
to 20/80; see Table 1). Final median postoperative vision
was 20/30, with visual acuity ranging from 20/20 to
20/40 (p = 0 0232). Visual improvement was observed for
all patients (100%), and the average visual gain was +3.0 lines
of vision. Two patients had 4 lines of visual improvement, 2
additional patients improved by 3 lines, and the final patient
gained 1 line of vision. The median preoperative CMT
foveal was 347 microns and decreased to a median of
152 microns (p = 0 0253) following intervention.
4. Discussion
This retrospective study demonstrates that combination
therapy using bevacizumab and thermal laser for peripapil-
lary CNVM improves vision and metamorphopsia, decreases
CMT on OCT, and may limit CNVM recurrence.
Various interventional strategies for peripapillary CNVM
have been utilized with modest to moderate results for visual
improvement. In studies using thermal laser alone, vision
remained stable or improved in 75%–80% of eyes after treat-
ment [1, 5–8]. However, MPS data for peripapillary CNVM
demonstrated only a slight visual benefit with laser treat-
ment. Only 50% of treated eyes retained 20/40 or better
vision versus 44% in the untreated group in the study. Addi-
tionally, 14% of treated eyes versus 26% of untreated eyes lost
6 or more lines of vision [9]. Browning and Fraser [1] like-
wise reported modest visual improvement (7.8%) and
increased worsening of vision (24.5%) in comparison, along
with 67.5% of eyes as stable, after thermal laser treatment
alone. Visual improvement was defined as a gain of greater
than or equal to 3 lines, worse vision as a loss of 3 lines,
and stability as either a loss or a gain of 2 lines. PDT data pre-
sented by Rosenblatt et al. [10] had an average of 2 lines of
visual gain, while Bernstein and Horn [11] stated that all
patients had visual gain. Studies involving surgical interven-
tion for OHS reported 57.5% (23/40) of patients having 2
or more lines of visual gain [9].
Bevacizumab has been used alone to treat peripapillary
CNVM [14, 15]. Figueroa et al. [14] treated 6 eyes with bev-
acizumab, including 2 after surgery and 1 eye with previous
PDT treatment. Five eyes showed regression of the CNVM
after 3 injections, while 1 eye required 6 injections. The
reported visual outcomes were positive with an average of 4
lines increase in vision. Hoeh et al. [15] likewise demon-
strated inactivation of CNVM lesions with an average of 3.5
injections (range 1–8). However, the follow-up after the last
injection was rather brief, thus limiting available data regard-
ing long-term visual improvement or stability.
In this study, using a combination of bevacizumab and
thermal laser, 5/5 eyes (100%) had visual improvement
with 4/5 eyes (80%) gaining 3 or more lines of vision.
One patient, whose eye initially improved by 2 lines, ulti-
mately resulted in 1 line of visual gain due to both eyes
worsening from cataracts unrelated to the retina during
the follow-up period. Four out of 5 patients were phakic,
and 3 of the 4 eyes had moderately significant cataracts.
Interestingly, the final vision obtained for these patients
was the same in each eye. Thus, it is possible that cataract
removal may lead to further visual improvements.
In each case at presentation, the CNVM was surrounded
with subretinal hemorrhage, exudates, and subfoveal fluid
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resulting in decreased vision. After a series of 3 intravitreal
bevacizumab injections, on average, the hemorrhage, subfo-
veal fluid, and exudates were resolved and the entire lesion
was well-defined clinically and on FA. This allowed for direct
and precise treatment of the CNVMwith thermal laser. Since
the total area of the CNVM was smaller after the bevacizu-
mab injections, the total area of retina requiring treatment
was also much smaller compared to the initial presentation,
limiting excess thermal damage to the neurosensory retina.
The use of bevacizumab or laser photocoagulation alone
has also been associated with recurrence of subretinal fluid.
Therefore, a single injection of bevacizumab was given
following thermal laser to limit potential upregulation of
VEGF and regrowth of CNVM due to photocoagulation.
Recurrence is a significant measure of therapeutic success
and patients’ improvement of quality of life. Previous studies
using thermal laser treatment alone reported recurrence rates
from 19% to 28% [1, 5–8]. Likewise, for treatments with
intravitreal bevacizumab alone, Davis et al. [18] reported
hemorrhage recurrence in nearly 30% of eyes during an
average of 8.3 months follow-up following an average of 5.6
total injections. Subretinal fluid for 15% of eyes never
resolved. High recurrence rates have also been reported with
the use of other treatment modalities. Rosenblatt et al. [10]
a (b) (c)
Figure 1: Retinal changes on fundoscopy, FA, and OCT throughout the treatment course. (a) At presentation, with fundus photos, FA, and
OCT; (b) after Avastin treatments, prior to thermal ablation of the CNVM; and (c) after thermal laser and final Avastin treatment.
Table 1: Summary of data of patients treated with Avastin followed by thermal laser and Avastin for peripapillary CNVM.
Patient
Baseline Number of injections
prior to combo therapy
Final Number of months of follow-up
after combo therapyVA CRT VA CRT
1 20/40 328 2 20/20 186 26
2 20/80 347 3 20/40 152 28
3 20/40 367 3 20/20 145 21
4 20/50 ∗ 2 20/40 130 23
5 20/70 ∗ 4 20/30 181 22
VA, visual acuity; CRT, central retinal thickness; ∗information not available.
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treated 7 patients with PDT and 5/7 (71.4%) required retreat-
ment. Bernstein and Horn [11] likewise treated 7 patients
with PDT and 2/7 patients (28.6%) required retreatment with
PDT despite 4/7 (57.1%) of these patients having been
previously treated with other modalities including intravit-
real triamcinolone, pegaptanib, or ranibizumab. In studies
involving surgical removal of CNVM associated with OHS,
the recurrence rate was 22.5% (9/40 patients).
In this study, we report no recurrences with our treat-
ment regimen. It is likely that the bevacizumab not only
caused the involution of the CNVM but also aided in the
reabsorption of the hemorrhage and exudates via inhibition
of vascular endothelial growth factor (VEGF). In turn, this
allowed for a more precise and thorough laser treatment of
the entire lesion with a 200-micron temporal border. More-
over, recurrence has been shown to occur at lesion edges
within the first 6 weeks to one year after treatment with ther-
mal laser alone [19]. Recurrence or persistence of CNVM, or
development of new CNVM and further visual deterioration
after adequate thermal laser surgery, is usually a result of
disease process and is not a complication. The bevacizumab
injection given shortly after the thermal laser treatment likely
inhibited this recurrence mechanism by mitigating potential
upregulation of VEGF associated with laser treatment.
Recurrence was absent for all patients in this study well
beyond one year of follow-up, with an average follow-up of
24 months. While the results of this series are clearly positive,
the study is limited by its retrospective design, small sample
size, and the use of non-ETDRS vision. Further investigation
is warranted with greater patient numbers and updated
study design.
Bevacizumab and thermal laser combination therapy
appears to be a promising treatment option for peripapillary
CNVM. Initial treatment with bevacizumab may resolve
hemorrhage-, edema-, and exudate-associated CNVM,
reducing the total area of CNVM and retina requiring ther-
mal laser. This strategy may also limit the total number of
bevacizumab injections required, minimizing adverse conse-
quences, while achieving increased visual acuity that remains
stable over extended periods of time without recurrence.
Together, this points to bevacizumab and thermal laser com-
bination therapy as a favorable treatment strategy for
improving patient visual function and decreasing CMT,
while limiting the potential for recurrence and adverse
effects.
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